Zhejiang Hisun Pharmaceutical Co Ltd (600267):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Zhejiang Hisun Pharmaceutical Co Ltd (600267) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7619
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Zhejiang Hisun Pharmaceutical Co Ltd (Hisun) is a pharmaceutical company that manufactures and commercializes active pharmaceutical ingredients, antibiotics and anticancer drugs. The company offers active pharmaceutical ingredients and bulk drugs used in anti-neoplastics. It offers products in the areas of cardiovascular, anti-infection, anti-parasite, endocrine control, immunoinhibitors and anti-depression. Hisun offers active pharmaceutical ingredient such as acarbose, adenosine, bicalutamide, irbesartan, mevastatin, pitavastatin calcium, cladribine, cyclophosphamaide, rosuvastatin calcium, meropenem, imipenem, daptomycin, tobramycin and others. Hisun also offers contract manufacturing services. The company operates through its research and development facilities located in Shanghai and Beijing. Hisun is headquartered in Taizhou, Zhejiang, China.

Zhejiang Hisun Pharmaceutical Co Ltd (600267) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Zhejiang Hisun Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
Infectious Disease Research Institute Enters into Agreement with Zhejiang Hisun Pharma 14
GeneriCo Enters into Distribution Agreement with Zhejiang Hisun Pharmaceutical 15
Celsion Enters into Agreement with Zhejiang Hisun Pharma 16
Zhejiang Hisun Pharma Enters into Memorandum of Understanding (MoU) with Sanofi 17
Zhejiang Hisun Pharma to Enter Co-Development Agreement with Ambrx 18
Catalent Pharma Enters Into An Agreement With Zhejiang Hisun Pharma To Develop Biosimilars 19
Celsion Expands Technology Development Agreement With Zhejiang Hisun Pharma 20
Celsion Enters Into Technology Development Agreement With Zhejiang Hisun Pharma For ThermoDox 21
Pfizer Forms Joint Venture With Zhejiang Hisun Pharma For Generic Medicines 23
Zhejiang Hisun Pharma to Form Joint Venture With Beijing-Based Technology Company 24
Enzon Pharma Enters Into Co-Development Agreement With Zhejiang Hisun Pharma 25
Licensing Agreements 26
Zhejiang Hisun Pharma Enters into Licensing Agreement with Nascent Biotech 26
Zhejiang Hisun Pharma Enters into Licensing Agreement with Eli Lilly for Capreomycin 27
Enzon Pharma Enters Into Licensing Agreement With Zhejiang Hisun Pharma For PEG-SN38 28
Zhejiang Hisun Pharma Enters into Licensing Agreement with Fujifilm 29
Equity Offering 30
Zhejiang Hisun Pharma Plans to Raise up to USD143.8 Million in Private Placement of Shares 30
Zhejiang Hisun Pharma Receives Regulatory Approval for Private Placement of Shares 31
Debt Offering 32
Zhejiang Hisun Pharma Raises USD307.6 Million in Public Offering of Bonds 32
Zhejiang Hisun Pharma Prices Private Placement of Bonds for USD184 Million 33
Zhejiang Hisun Pharma Announces Private Placement Of Notes For Up To US$327 Million 34
Zhejiang Hisun Pharma Announces Public Offering Of Bonds 35
Acquisition 36
Zhejiang Hisun Pharma to Acquire 68% Stake in China Based Pharma Company for USD24.5 Million 36
Zhejiang Hisun Pharma Plans to Divest Stake in Sagent Pharma 37
Zhejiang Hisun Pharma to Acquire 15% Stake in Zhejiang-Based Pharma Company for USD12 Million 38
Zhejiang Hisun Pharma Acquires Respirics, Respiratory Drug Developer 39
Zhejiang Hisun Pharmaceutical Co Ltd – Key Competitors 40
Zhejiang Hisun Pharmaceutical Co Ltd – Key Employees 41
Zhejiang Hisun Pharmaceutical Co Ltd – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Joint Venture 42
Recent Developments 43
Other Significant Developments 43
Jul 20, 2017: HISUN’s first intelligent FDF production line is put operation on July 20th 2015 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zhejiang Hisun Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Zhejiang Hisun Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Infectious Disease Research Institute Enters into Agreement with Zhejiang Hisun Pharma 14
GeneriCo Enters into Distribution Agreement with Zhejiang Hisun Pharmaceutical 15
Celsion Enters into Agreement with Zhejiang Hisun Pharma 16
Zhejiang Hisun Pharma Enters into Memorandum of Understanding (MoU) with Sanofi 17
Zhejiang Hisun Pharma to Enter Co-Development Agreement with Ambrx 18
Catalent Pharma Enters Into An Agreement With Zhejiang Hisun Pharma To Develop Biosimilars 19
Celsion Expands Technology Development Agreement With Zhejiang Hisun Pharma 20
Celsion Enters Into Technology Development Agreement With Zhejiang Hisun Pharma For ThermoDox 21
Pfizer Forms Joint Venture With Zhejiang Hisun Pharma For Generic Medicines 23
Zhejiang Hisun Pharma to Form Joint Venture With Beijing-Based Technology Company 24
Enzon Pharma Enters Into Co-Development Agreement With Zhejiang Hisun Pharma 25
Zhejiang Hisun Pharma Enters into Licensing Agreement with Nascent Biotech 26
Zhejiang Hisun Pharma Enters into Licensing Agreement with Eli Lilly for Capreomycin 27
Enzon Pharma Enters Into Licensing Agreement With Zhejiang Hisun Pharma For PEG-SN38 28
Zhejiang Hisun Pharma Enters into Licensing Agreement with Fujifilm 29
Zhejiang Hisun Pharma Plans to Raise up to USD143.8 Million in Private Placement of Shares 30
Zhejiang Hisun Pharma Receives Regulatory Approval for Private Placement of Shares 31
Zhejiang Hisun Pharma Raises USD307.6 Million in Public Offering of Bonds 32
Zhejiang Hisun Pharma Prices Private Placement of Bonds for USD184 Million 33
Zhejiang Hisun Pharma Announces Private Placement Of Notes For Up To US$327 Million 34
Zhejiang Hisun Pharma Announces Public Offering Of Bonds 35
Zhejiang Hisun Pharma to Acquire 68% Stake in China Based Pharma Company for USD24.5 Million 36
Zhejiang Hisun Pharma Plans to Divest Stake in Sagent Pharma 37
Zhejiang Hisun Pharma to Acquire 15% Stake in Zhejiang-Based Pharma Company for USD12 Million 38
Zhejiang Hisun Pharma Acquires Respirics, Respiratory Drug Developer 39
Zhejiang Hisun Pharmaceutical Co Ltd, Key Competitors 40
Zhejiang Hisun Pharmaceutical Co Ltd, Key Employees 41
Zhejiang Hisun Pharmaceutical Co Ltd, Joint Venture 42

List of Figures
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zhejiang Hisun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Zhejiang Hisun Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Zhejiang Hisun Pharmaceutical Co Ltd (600267):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Chagala Group Limited:企業の戦略・SWOT・財務情報
    Chagala Group Limited - Strategy, SWOT and Corporate Finance Report Summary Chagala Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Sanchez Midstream Partners LP (SPP):企業の財務・戦略的SWOT分析
    Summary Sanchez Midstream Partners LP (SMP), formerly Sanchez Production Partners LP, a subsidiary of Sanchez Oil & Gas Corp, is an oil and gas company that acquires, develops and operates midstream and other energy related assets. The company offers drilling results, production, and hedging service …
  • Lion Energy Ltd (LIO):企業の財務・戦略的SWOT分析
    Summary Lion Energy Ltd (Lion) is an oil and gas company that explores, develops and produces unconventional oil and gas resources in Indonesia. The company has conventional production sharing contracts such as Seram project and South Block A project. Its Seram project is located on the island of Se …
  • Voith GmbH & Co KGaA:企業の戦略的SWOT分析
    Voith GmbH & Co KGaA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Academia Sinica-製薬・医療分野:企業M&A・提携分析
    Summary Academia Sinica is an academic institution that promotes and undertakes research activities in the disciplines of mathematics and physical sciences, life sciences, and humanities and social sciences. The institution integrates research activities to improve the planning, implementation, and …
  • Windflow Technology Limited (WTL):企業の財務・戦略的SWOT分析
    Windflow Technology Limited (WTL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Collagen Solutions Plc (COS)-医療機器分野:企業M&A・提携分析
    Summary Collagen Solutions Plc (Collagen Solutions), formerly Healthcare Investment Opportunities Plc is a medical device company that develops, manufactures and supplies medical grade collagen biomaterials and components. The company offers sourcing and supply of high grade collagen; provision of f …
  • Ceska Sprava Socialniho Zabezpeceni:企業の戦略的SWOT分析
    Ceska Sprava Socialniho Zabezpeceni - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • HearMeOut Ltd (HMO):企業の財務・戦略的SWOT分析
    HearMeOut Ltd (HMO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Bouwinvest Real Estate Investment Management B.V.:企業の戦略・SWOT・財務情報
    Bouwinvest Real Estate Investment Management B.V. - Strategy, SWOT and Corporate Finance Report Summary Bouwinvest Real Estate Investment Management B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structur …
  • Detour Gold Corp:企業の戦略・SWOT・財務分析
    Detour Gold Corp - Strategy, SWOT and Corporate Finance Report Summary Detour Gold Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • VWR International LLC-医療機器分野:企業M&A・提携分析
    Summary VWR International LLC (VWR), a subsidiary of VWR Corp is a medical device company that offers healthcare equipment. The company’s products comprise adhesive dispensers, adhesive labels, adhesive slides, agarose and acrylamide, air freshener dispensers, air regulation valves, aluminum foil, a …
  • salesforce.com, inc.:戦略・SWOT・企業財務分析
    salesforce.com, inc. - Strategy, SWOT and Corporate Finance Report Summary salesforce.com, inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Telekom Malaysia Berhad:企業の戦略・SWOT・財務情報
    Telekom Malaysia Berhad - Strategy, SWOT and Corporate Finance Report Summary Telekom Malaysia Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Mediware Information Systems Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Mediware Information Systems Inc (Mediware), a subsidiary of TPG Capital is a healthcare solutions company that designs, develops and commercializes specialized healthcare software. It provides software to healthcare and human service providers and payers. The company’s portfolio of solution …
  • Time Dotcom Berhad (TIMECOM):企業の財務・戦略的SWOT分析
    Time Dotcom Berhad (TIMECOM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Synthon Holdings BV:企業の戦略的SWOT分析
    Synthon Holdings BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Service Corporation International:企業の戦略・SWOT・財務分析
    Service Corporation International - Strategy, SWOT and Corporate Finance Report Summary Service Corporation International - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Altona Energy Plc:企業の戦略・SWOT・財務分析
    Altona Energy Plc - Strategy, SWOT and Corporate Finance Report Summary Altona Energy Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Maastricht University:製薬・医療:M&Aディール及び事業提携情報
    Summary Maastricht University (MU) is an educational service provider that offers academic programs such as bachelor degree, master and doctoral programs. The university offers postgraduate research degrees in various subjects for a range of research needs and interests. It offers programs through i …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆